The patients have been followed for between two and eight months after the kidney transplant, with most patients followed for three or more months. Patient follow-up is continuing. As previously reported, in a 275-patient Phase III trial, the incidence of rejection episodes within six months of transplantation among patients receiving Zenapax, cyclosporine and prednisone was 28 percent. In another multinational Phase III trial, the incidence of rejection episodes among patients receiving Zenapax, cyclosporine, prednisone and azathioprine was 22 percent. Dr. Vincenti also reported on the average creatinine levels of the patients in the cyclosporine elimination trial.
Creatinine level is a measure of kidney function, with lower levels indicating improved function.
The improved creatinine level suggests that the elimination of cyclosporine in the current trial may lead to better kidney function. Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer. All rights reserved.